Alnylam's ATTR cardiomyopathy drug backed for NHS use Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.

#Patients in England and Wales with #cardiomyopathy caused by the disorder #ATTRamyloidosis will soon be able to access treatment with #Alnylam's gene-silencing drug #Amvuttra.

NEWS: #Alnylam has the FDA approval it sought for Amvuttra in a form of #cardiomyopathy associated with rare disease #ATTRamyloidosis, allowing it to compete head-to-head with rival therapies from #Pfizer and #BridgeBio.

pharmaphorum.com/news/alnylam...